fda ban semaglutide on compounding news alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products The FDA's Decision to – FDA approves obesity drug that – 🚨There's been a lot of

Several macro and micro-level drivers are driving this obesity care revolution: Rising Prevalence : By 2030, nearly half the worlds population will be living with overweight or obesity, an alarming epidemiological trend that brings public health systems to a tipping point

During these first four weeks, your body starts adjusting to the medications effects

Acute caffeine ingestion improves 3-km run performance, cognitive function, and psychological state of young recreational runners

Higher-risk patterns: losing more than 1 kg per week losing 1520% of body weight steep calorie restriction skipping meals because of nausea or early satiety Fast change metabolic stress shedding

Like their injectable versions, GLP-1 pills can cause gastrointestinal issues